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WT1 expression in breast 
cancer disrupts the epithelial/
mesenchymal balance of tumour 
cells and correlates with the 
metabolic response to docetaxel
Mara Artibani1,†, Andrew H. Sims1, Joan Slight1, Stuart Aitken1, Anna Thornburn1, 
Morwenna Muir1, Valerie G. Brunton1, Jorge Del-Pozo2, Linda R. Morrison2, Elad Katz1,‡, 
Nicholas D. Hastie1 & Peter Hohenstein1,3
WT1 is a transcription factor which regulates the epithelial-mesenchymal balance during embryonic 
development and, if mutated, can lead to the formation of Wilms’ tumour, the most common paediatric 
kidney cancer. Its expression has also been reported in several adult tumour types, including breast 
cancer, and usually correlates with poor outcome. However, published data is inconsistent and the role 
of WT1 in this malignancy remains unclear. Here we provide a complete study of WT1 expression across 
different breast cancer subtypes as well as isoform specific expression analysis. Using in vitro cell lines, 
clinical samples and publicly available gene expression datasets, we demonstrate that WT1 plays a 
role in regulating the epithelial-mesenchymal balance of breast cancer cells and that WT1-expressing 
tumours are mainly associated with a mesenchymal phenotype. WT1 gene expression also correlates 
with CYP3A4 levels and is associated with poorer response to taxane treatment. Our work is the first to 
demonstrate that the known association between WT1 expression in breast cancer and poor prognosis 
is potentially due to cancer-related epithelial-to-mesenchymal transition (EMT) and poor chemotherapy 
response.
The Wilms’ Tumour gene 1 (WT1), encodes for a complex protein with transcription factor activity which is 
essential in mammals throughout life1. Its roles vary with the developmental stages: in the embryo, it regulates 
the epithelial-mesenchymal balance required for a correct organogenesis and acts as a tumour suppressor in the 
aetiology of Wilms’ tumour2,3; in the adult, it is involved in the maintenance of tissue homeostasis and has been 
controversially considered as an oncogene in leukaemia and several solid tumours, including breast cancer4. The 
role of WT1 in this malignancy is unclear, despite the accumulation of a considerable body of data over the last 
fifteen years. Several groups have reported WT1 expression in breast cancer, but the data on the percentage of 
WT1-positive tumours are highly discordant, most likely because of differences in the detection method, anti-
body specificity and histological subtype5–11. Moreover, there is evidence for both oncogenic and tumour sup-
pressing functions6,7,12 and these contradictory results can be explained only in part by the presence of different 
isoforms13.
One study has associated WT1 with improved outcomes14, however most literature seems to indicate that high 
WT1 expression is associated with poor prognosis in breast cancer patients8,15. The biological basis behind these 
seemingly inconsistent findings has not yet been identified, but several hypotheses have been formulated. Firstly, 
tumours expressing high levels of WT1 may have a proliferative advantage since silencing WT1 leads to growth 
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arrest and apoptosis16–19. Investigations on the molecular mechanisms involved in this process have revealed that 
WT1 can modulate many genes of the BCL2 family, including BAK, BAG3, BCL2A1 and BCL2 itself 20–22 as well 
as regulate the Fas-related death signalling pathway23; moreover, there is some evidence suggesting that WT1 can 
promote cell proliferation by up-regulating cyclin D124.
A second hypothesis is related to blood vessel formation. WT1 has been detected in the vasculature of differ-
ent tumour types25,26 and its expression in endometrial cancer has been associated with the induction of angio-
genesis27. In addition, WT1 directly upregulates the expression of the vascular endothelial growth factor (VEGF)28 
as well as regulating its splicing29. Many other vascular genes have been identified as potential WT1 targets, 
including the vascular endothelial cadherin, angiopoietin-2, vascular endothelial growth factor receptors 1 and 
230. Most importantly, the endothelial knockout of WT1 has been shown to reduce both tumour angiogenesis and 
growth in vivo31, suggesting that this gene is a major regulator of blood vessel formation in cancer.
Finally, an alternative hypothesis relies on the fact that WT1 is a key regulator of the epithelial/mesenchymal 
balance during development and therefore it may also play a role in the EMT of tumour cells1. Besides being 
recently linked to chemoresistance32,33, cancer-related EMT has long been associated with the acquisition of a 
malignant phenotype by the epithelial tumour cells: features of EMT have been described in breast34 and colorec-
tal cancer35, mainly at the invasive front of the tumour. This suggests that the EMT may generate migratory cells 
which leave the primary site, invade the blood vessels and potentially metastasise. This theory on EMT contri-
bution to tumour progression is supported by the fact that many developmental EMT drivers, including SNAIL, 
SLUG, TWIST and ZEB1, are aberrantly expressed in cancer and significantly correlate with relapse and poor 
clinical outcomes36–38. Importantly, WT1 has been shown to regulate the EMT which occurs in the develop-
ing epicardium2 as well as the MET which is required for nephrogenesis3 and its transcriptional targets include 
SNAIL, SLUG and TGF-β2,39,40.
In the present work, we have studied the relationship between WT1 expression and the overall epithelial/mes-
enchymal balance of breast cancer using in vitro cell lines, clinical samples and publicly available gene expression 
datasets in order to better investigate why WT1 is usually associated with poor prognosis.
Results
Different WT1 isoforms are observed in breast cancer and their expression is higher in the 
ER-positive subtype. Several groups have described WT1 expression in breast cancer5–11, however the data 
is inconsistent and the frequency of WT1-positive tumours varies from 23%6 to 87%7. Such discrepancies may be 
due to different detection techniques or antibody specificity11, but may also be related to differences in the molec-
ular subtype of the tumours or to different WT1 isoforms.
In order to overcome these limitations, we have performed a more detailed and comprehensive analysis of 
WT1 expression in breast cancer using different approaches (in vivo, in vitro and in silico).
Firstly, we analysed WT1 expression in an integrated dataset from 17 studies representing 2999 primary 
human breast cancers41 (Fig. 1A). The transcript could only be reliably detected (considering ‘Present’ detection 
calls in the Affymetrix data) in 11% of the tumours (329 out of the total 2999) and showed the highest expression 
Figure 1. WT1 expression in human primary breast cancer datasets. (A) Gene expression analysis data from 
17 integrated datasets (n = 2999 tumours). (B) Boxplot of WT1 expression in the different subtypes, y-axis 
showing log2 values. (C) Boxplots of WT1 expression in ER-positive (blue) and ER-negative (red) tumours 
designated by IHC of ER-alpha amongst those tumours with detectable expression of WT1, ***p < 0.001.
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level in the luminal subtype (Fig. 1B, Mann Whitney p value of 4.5e-7). Furthermore, restricting the samples to 
those in which WT1 was detected, WT1 expression was significantly higher in ER-positive than in ER-negative 
tumours (Fig. 1C, p = 1.2e-5).
Secondly, we analysed a locally derived cohort of invasive breast cancer samples (n = 44) using isoform-specific 
assays: quantitative RT-PCR was first performed using primers targeting exon 7/8 of WT1, in order to amplify all 
the known isoforms (Fig. 2A, Figure S1 in Additional file 1). Additional assays were then designed to specifically 
amplify a maternally-imprinted alternative exon 142 and the portion of intron 5 which is transcribed in the trun-
cated variant43 (Figure S1 in Additional file 1). To compare the expression levels of the different isoforms between 
healthy and neoplastic tissue, we also included a sample of human adult mammary gland. This normal tissue 
sample, a pool from 5 different healthy donors, expressed higher WT1 levels than any of the tumour samples, but 
lacked both the exon 1A and intron 5 isoforms.
Lastly, examination of WT1 expression in a panel of thirteen breast cancer cell lines by qPCR demonstrated 
that seven of the cell lines had detectable levels of WT1, with the highest expression observed in the basal 
triple-negative lines HBL100 and MDA-MB-157 and in the luminal ER+ line ZR75 (Fig. 2B). While the qPCR for 
the optional exon 5 mirrors the exon 7/8 results, only BT20 and MDA-MB-231 cells expressed detectable levels of 
the intron 5 isoform and exon 1A was expressed only by BT20 cells.
To further assess the extraordinary complexity of the WT1 locus, we also analysed a dataset representing a 
panel of 41 breast cancer cell lines using Affymetrix exon GeneChips (GSE16732)44.
The exon array data was largely in agreement with the qPCR experiments, showing high levels of WT1 
expression for ZR75, MDA-MB-157, HS578T and T47D cell lines (Fig. 2C); moreover, WT1 expression in 
MDA-MB-231 cells seemed to be restricted to exons 6 to 10, suggesting that this cell line may only express the 
truncated intron 5 isoform.
Knock-down of WT1 in the MDA-MB-157 line increases the motility, invasiveness and metastatic 
potential of breast cancer cells. An RNAi-based gene knockdown strategy was used to investigate the 
functional role of WT1 in breast cancer cells. Unlike previous studies based on transient transfections45, we 
achieved stable WT1 knockdown in three human breast cancer cell lines (Fig. 3A,B). Both constitutive and induc-
ible lentiviral vectors were used for MDA-MB-157 cells, which showed up to 70% mRNA and protein reduction 
(Fig. 3A–D).
RNA-seq was used to investigate the consequences of WT1 loss in the MDA-MB-157 cell line by comparing 
the transcriptomes of the wildtype and knockdown cells. Differential expression of 427 transcripts (Table S1 in 
Additional file 2) was observed, including several genes involved in RNA metabolism/biosynthesis, the neu-
ronal gene SEMA5A (reported to play a role in cancer progression46), and the ncRNA MALAT1 (a regulator of 
the metastasis phenotype in lung cancer47). ToppFun (http://toppgene.cchmc.org/enrichment.jsp)48 was used to 
functionally annotate the differentially expressed genes and it showed enrichment for genes involved in sev-
eral migration-related biological processes, from cell adhesion to cell projection morphogenesis/organisation 
(Table S2 in Additional file 2).
In order to assess if WT1 knockdown affects the motility of breast cancer cells, we performed migration and 
invasion assays. The cells in which WT1 was silenced displayed a statistically significant increase in both migra-
tory capacity and invasiveness when compared to pGIPZ-lacZ controls (p = 0.031 and p = 0.008 respectively) 
(Fig. 4A).
The knockdown cells also showed significantly increased incidence of lung metastases following injection 
into the tail vein of nude athymic mice (p = 0.011) (Fig. 4B), although the total tumour area was not significantly 
different between the two groups (Fig. 4C).
Knockdown and overexpression of WT1 disrupts the epithelial-mesenchymal balance of breast 
cancer cells. Since increased migration is considered a feature of EMT49, we determined if the loss of WT1 
also affects the epithelial/mesenchymal balance of breast cancer cells and analysed the RNA levels of several EMT 
drivers (SNAI1, SNAI2, ZEB1, ZEB2, TWIST1), epithelial markers (CTNNA1, CTNNA2, CTNND1, CDH1, KRT18) 
and mesenchymal markers (VIM, TNC, TGFB1, CDH2, MMP2, MMP9) through quantitative real-time PCR.
We also generated and analysed overexpression clones from two different lines using the full length cDNA of 
WT1 (Fig. 3E).
In the mesenchymal line MDA-MB-157, overexpressing WT1 pushes the cells towards a more epithelial pheno-
type, with increased expression of CTNNA1 and KRT18 as well as downregulation of VIM (Fig. 5A). On the other 
hand, silencing WT1 exacerbates their mesenchymal characteristics, with significant changes in the expression of 
EMT markers (Fig. 5A–C) along with a more elongated and irregular morphology, as shown by phalloidin staining 
(Fig. 6A). Moreover, even though no significant differences are observed at the mRNA level, the knockdown cells 
display nuclear accumulation of CDH1 (Fig. 6C), a feature that has been linked to increased tumour invasion50.
Some of these results, such us the upregulation of TNC upon WT1 loss, were replicated in the other mesenchy-
mal line used in this study, MDA-MB-231 (Figure S3 in Additional file 1). However, completely opposite results 
were observed in the epithelial line HBL100, where WT1 overexpression led to the up-regulation of mesenchymal 
markers (Fig. 5B).
In order to understand which scenario more closely represents what happens in vivo, we compared the 
expression of EMT-related transcripts (VIM, SNAI1, SNAI2, TWIST1, CDH1, CDH3, CLDN7, TNC) between 
WT1-positive and WT1-negative samples from the integrated dataset described in Fig. 1A: statistically significant 
differences were only observed for the mesenchymal genes VIM, SNAI1 and TNC, which showed higher expression 
in the WT1-positive samples (p-value < 0.001, < 0.05, < 0.001 respectively) (Fig. 5D, Figure S4 in Additional file 1).
www.nature.com/scientificreports/
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Figure 2. WT1 expression in breast cancer cell lines. (A) Schematic of the WT1 locus, showing alternative 
exons/splices in red, the position of the primers for each qRT-PCR assay and the sequence targeted by the 
shRNA used in the knockdown experiments. (B) Quantitative real-time PCR of WT1 mRNA: data points 
represent the relative expression for each assay, error bars represent the standard deviation of two biological 
replicates. (C) Heatmap visualization of the relative expression of probes representing each WT1 exon 
across a panel of breast cancer cell lines in a published dataset (GSE16732). The different colours indicate 
the cell line subtype (red = basal, orange = basal B/mesenchymal, purple = HER2 amplified, blue = luminal, 
yellow = claudin-low).
www.nature.com/scientificreports/
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The results were further validated with the locally derived cohort previously described: the patient samples 
were first sorted according to their levels of WT1 (Figure S1 in Additional file 1), then qPCR was used to assess 
the expression of the mesenchymal markers VIM, SNAI1 and TNC (Fig. 5E). The WT1-postive tumours had 
higher expression of all three markers, even though statistical significance was only achieved for TNC.
Down-regulation of WT1 does not result in changes in proliferation, apoptosis or cancer stem 
cell characteristics. Transient silencing of WT1 has been previously shown to inhibit proliferation and 
induce apoptosis in cultures originated from leukemic cells and several solid tumours16–18,45, therefore we also 
Figure 3. WT1 knockdown and overexpression is achieved in breast cancer cell lines. (A) Quantitative real-
time PCR of WT1 mRNA in MDA-MB-157, MDA-MB-231 and HBL100 cells transduced with pGIPZ-miR:  
the graph represents fold change of mean expression relative to untransduced cells (given a value of 1); error 
bars represent the standard deviation of two separate biological replicates (**p < 0.01, ***p < 0.001).  
(B) Immunoblot of whole-protein lysates (40 μ g) probed with antibodies to WT1 and HSP90, as a loading 
control. Only the truncated isoform of WT1 can be observed in MDA-MB-231 cells. Full-length blots are 
presented in Figure S8 in Additional file 1. (C) WT1 immunofluorescence of MDA-MB-157 cells transduced 
with pGIPZ-miR. (D) Quantitative real-time PCR of WT1 mRNA in MDA-MB-157 cells transduced with 
pTRIPZ-miR: the cells were cultured on 2 μ g/ml doxycycline, the graph represents fold change of mean 
expression relative to untransduced cells, error bars represent the standard deviation of three biological 
replicates (*p < 0.05, **p < 0.01, ***p < 0.001). (E) Quantitative real-time PCR of WT1 mRNA in MDA-MB-157 
and HBL100 cells transfected with pCI-WT1-OE; data points represent the relative expression, error bars 
represent the standard deviation of three biological replicates (***p < 0.001, ****p < 0.0001).
www.nature.com/scientificreports/
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performed apoptosis and cell cycle analysis. However, our knockdown cells did not show any significant change in 
either of these (Figures S5–6 in Additional file 1), suggesting that, at least for breast cancer cells with stable WT1 
knockdown, the main phenotype is the disruption of the epithelial/mesenchymal balance, rather than apoptosis 
or cell cycle effects.
Since the EMT process has been linked to the acquisition of cancer stem-cell properties (e.g., an increased 
ability to form spheres in colony-forming assays or the expression of stem-cell markers)51, we also analysed 
stem-cell characteristics in the WT1 knockdown cells.
No statistically significant difference in mammosphere formation was observed in any of the three lines 
used in this study (Fig. 7A). The cancer stem cell content of the knockdown cells was analysed by quantifying 
the sub-population of CD44+ /CD24− cells, which has been reported to be highly enriched in CSCs51. In the 
MDA-MB-157 line the percentage of CD44+ /CD24− cells did not change significantly upon WT1 loss (Fig. 7B), 
suggesting that down-regulation of WT1 does not affect the ‘stemness’ of breast cancer cells.
WT1 expression correlates with CYP3A4 levels and is associated with poorer response to taxane 
treatment. In order to identify differentially expressed genes between WT1-positive and WT1-negative breast 
tumours, significance analysis of microarray (SAM) was performed using the publicly available datasets previ-
ously described41. Among the 500 most significantly differentially expressed transcripts (Table S3 in Additional 
file 2) there are several different types of metalloproteases and many genes belonging to the cytochrome P450 
family (CYP), all of which are significantly (p < 0.0001) positively correlated with WT1 (Fig. 8A).
These oxidising enzymes play an important and complex role in the metabolism of anti-cancer agents: 
they participate in the biological activation of many pro-drugs, but also to the inactivation of some cytotoxic 
compounds, two processes that occur predominantly, but not exclusively, in the liver. Not surprisingly, poly-
morphisms and different expression levels of the CYP genes have been shown to influence the outcome of chem-
otherapeutic treatments52.
The substrates of one of these up-regulated genes, CYP3A4, include drugs routinely used in the management 
of breast cancer such as tamoxifen, docetaxel, paclitaxel, cyclophosphamide and doxorubicin52. More specifically, 
CYP3A4 activity in the liver is responsible for the activation of tamoxifen and cyclophosphamide, whereas it 
transforms docetaxel into inactive hydroxylated derivatives; interestingly, high CYP3A4 levels in breast cancer 
biopsies can predict a poor therapeutic response to docetaxel, which suggests that also the enzyme within the 
tumour is involved in the inactivation of this drug53.
Given this association between WT1 and CYP3A4 expression in breast cancer (Fig. 8B), we decided to investi-
gate whether the tumour levels of WT1 can be used to predict the response of breast cancer patients to docetaxel. 
To do so, we analysed a publicly available gene expression dataset (GSE25065) of 198 HER2-negative breast can-
cer cases treated with taxane-anthracycline chemotherapy pre-operatively and endocrine therapy if ER-positive54. 
Figure 4. Knockdown of WT1 results in increased motility, invasiveness and metastatic potential of 
MDA-MB-157 cells. (A) Bar diagram representing the mean number of migrating and invading cells from three 
independent experiments. (B,C) WT1 knockdown significantly increases the number (B) but not the size (C) of 
lung metastases. MDA-MB-157 cells transduced with pGIPZ-miR were injected into nude mice through the tail 
vein and lung metastases were assessed 8 weeks after injection (n = 4 for each group).
www.nature.com/scientificreports/
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Figure 5. Correlation between WT1 expression and EMT markers in vitro and in vivo. (A) Quantitative 
real-time PCR of epithelial and mesenchymal markers in MDA-MB-157 cells transduced with pGIPZ-miR or 
transfected with pCI-WT1-OE: the graph represents fold change of mean expression relative to control cells, 
error bars represent the standard deviation of three biological replicates (*p < 0.05, **p < 0.01). (B) Quantitative 
real-time PCR of mesenchymal markers in HBL100 cells transduced with pGIPZ-miR or transfected with pCI-
WT1-OE: the graph represents fold change of mean expression relative to control cells, error bars represent the 
standard deviation of three biological replicates (**p < 0.01, ***p < 0.001). (C) Quantitative real-time PCR of 
TNC, TGFB1 and ZEB2 mRNA in MDA-MB-157 cells transduced with pTRIPZ-miR: data points represent the 
relative expression of the gene, error bars represent the standard deviation of three separate biological replicates 
(**p < 0.01). (D) Boxplot of EMT genes expression in the WT1-positive and WT1-negative samples obtained 
from 17 integrated datasets (n = 2999 tumours), y-axis showing log2 values. Statistically significant differences 
were observed only for VIM, SNAI1 and TNC, which showed higher expression in the WT1-positive samples. 
*p < 0.05, ****p < 0.0001. (E) Quantitative RT-PCR of EMT genes in clinical samples (n = 44 tumours).
www.nature.com/scientificreports/
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Figure 6. EMT markers immunofluorescence in MDA-MB-157 cells. MDA-MB-157 cells transduced with 
pGIPZ-miR were stained with phalloidin toxin (A), vimentin/cytokeratin18 (B) and E-cadherin (C) antibodies.
www.nature.com/scientificreports/
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As shown in Fig. 8C, WT1 expression is significantly associated with poorer response and survival, with the 
5-year recurrence-free percentage in the WT1-positive patients being 20% lower than in the WT1-negative (p 
value = 0.0072). To further validate these results, CYP3A4 expression levels were analysed in the MDA-MB-157 
line and showed significant down-regulation upon WT1 loss (p = 0.035) (Fig. 8D); the WT1 knockdown cells also 
displayed increased sensitivity to docetaxel if compared to GIPZ-lacZ control (Fig. 8E).
Discussion
Despite extensive studies, the role of WT1 in breast cancer and its significance in terms of prognosis remain 
unclear, with conflicting results being reported in the literature.
Since this malignancy is a very heterogeneous disease and the WT1 locus is extremely complex, we started 
our study with a comprehensive assessment of WT1 expression in the different tumour subtypes followed by an 
isoform specific expression analysis.
Our work shows that WT1 expression in breast cancer occurs at low frequency (10–30%), and it is lower than 
in the healthy mammary gland, which is in agreement with some of the earlier studies on the topic5,6. Also, WT1 
expression is significantly higher in ER-positive (luminal) than in ER-negative (basal) tumours. This finding may 
be of particular interest, given that WT1 has been shown to both interact with ERα and modulate its expression 
in vitro55.
In terms of isoform expression pattern, all our data corroborate the hypothesis that the truncated transcript 
starting from intron5 is a tumour-specific isoform: this short WT1 variant was first detected in the blood of 
patients affected by acute leukaemia, then in breast and pancreatic cancer cell lines43,56 and we have now shown 
that it is expressed in human breast cancer biopsies, but is absent in the healthy mammary gland.
Both our in vitro and in silico experiments also seem to demonstrate that the truncated intron5 is the only 
WT1 isoform expressed in MDA-MB-231 cells; if confirmed, any assay targeted against exon1/5 would give a neg-
ative result, which may explain why the reports on WT1 expression in this cell line are so contradictory7,24,45,57,58.
Figure 7. Knockdown of WT1 does not affect CSCs percentage or colony forming ability. (A) Colony 
forming assay of MDA-MB-157, MDA-MB-231 and HBL100 cells with constitutive WT1 knockdown 
suspended in semi-solid medium. Data points represent the average number of spheres formed per well, 
error bars represent the SEM of four biological replicates. (B) FACS analysis of CD24 and CD44 expression in 
MDA-MB-157 cells transduced with pGIPZ-miR and pTRIZ-miR. Bar graphs represent the average percentage 
of CD44+ /CD24− cells in the different clones, error bars represent the SEM of three biological replicates.
www.nature.com/scientificreports/
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The last isoform we analysed, derived from a maternally imprinted alternative exon 142, has been detected in 
few human breast cancer samples and in only one cell line, suggesting that it is unlikely to play a major role in 
breast tumorigenesis.
WT1 expression in invasive ductal carcinoma has been associated with both improved14 and worse8 outcomes, 
while a third study, specifically on triple negative breast cancers15 has shown that high WT1 levels correlate with 
poor survival. WT1 expression in other adult tumours is usually associated with higher histological grade as well 
as worse prognosis59,60 and several hypotheses have been formulated to explain this association, such as altered 
proliferation/apoptosis16–19, increased angiogenesis25–27 and induction of cancer-EMT1.
In this study, we focused our analysis on the relationship between WT1 expression and the overall epithelial/
mesenchymal balance of breast cancer cells by developing the first stable WT1 knockdown in human breast can-
cer cells and extensively studying the effects of WT1 silencing as well as overexpression.
When we perturb the expression levels of WT1, either by knocking it down or over-expressing it, the breast 
cancer cells show a disruption of their epithelial-mesenchymal balance, which seems to be dependent on their 
Figure 8. WT1 expression in breast cancer correlates with cytochrome P450 family members and poor 
response to taxane treatment. (A) Heatmap showing ranked expression of WT1 alongside cytochrome P450 
genes obtained from 17 integrated published microarray datasets (n = 2999 tumours). (B) Boxplot of CYP3A4 
expression in the WT1-positive and WT1-negative samples. (C) Kaplan Meier survival analysis of 198 breast 
cancer patients treated with taxane-anthracycline chemotherapy (Dataset GSE25065) demonstrates that 
WT1 expression is associated with worse outcomes. Heatmaps show log2 mean-centered expression values, 
red = high, green = low. Shades of grey to white indicate p-values of log-rank (Mantel-Cox) tests at all possible 
cut-points are shown in grey. Vertical bars on survival curves indicate censored cases. (D) Quantitative real-
time PCR of CYP3A4 mRNA in MDA-MB-157 cells transduced with pGIPZ-miR: data points represent the 
relative expression of the gene, error bars represent the standard deviation of two separate biological replicates 
(*p < 0.05). (E) Cytotoxycity of docetaxel is increased in MDA-MB-157 cells transduced with pGIPZ-miR. 
Mean and standard deviation of three independent experiments are plotted (*p < 0.05).
www.nature.com/scientificreports/
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baseline characteristics. In particular, in mesenchymal-leaning lines such as MDA-MB-157 and MDA-MB-231, 
the loss of WT1 pushes them towards an even less epithelial phenotype, with increased motility, invasiveness and 
metastatic potential (as shown by the tail vein injection experiment). The opposite holds true for the epithelial 
line HBL100, where it is WT1 over-expression that leads to a more mesenchymal state. Such a dichotomous role 
is not surprising for WT1, which is known to regulate both EMT and MET in development2,3.
In terms of gene expression, the most significant changes are observed for the epithelial marker CTNNA1 (a 
catenin that maintains normal cell adhesion by forming a complex that anchors E-cadherin to the cell membrane 
and if disrupted can lead to tumour invasion) and the mesenchymal marker TNC (an extracellular matrix gly-
coprotein which is usually found at the invasive front of the tumour61 and has been shown to induce EMT-like 
changes and faster migration in breast cancer cells62). Interestingly, VEGF, which is an established WT1 target28 
is likely upstream of TNC63.
Overall, perturbing the expression levels of WT1 affects the epithelial/mesenchymal balance of cancer cells, 
but does not cause any significant change in cancer stem-cell properties, cell proliferation or apoptosis.
This finding is apparently in contrast with some previous experiments on leukemic and solid tumours cell 
lines, where the transient silencing of WT1 led to growth arrest and apoptosis16–18,45. However, the activation of 
an EMT program has been shown to protect from pro-apoptotic signals64: this could explain the discrepancy for 
MDA-MB-157 and MDA-MB-231 cells, which increase their mesenchymal features upon WT1 loss.
The in vitro experiments were then corroborated by the analysis of publicly available gene expression data-
sets of breast cancer cell lines and clinical samples: overall, the results are consistent with what observed in the 
HBL100 cell line and suggest that WT1 expression is usually associated with a more mesenchymal phenotype.
The gene expression analysis also revealed that the WT1-positive tumours exhibit poorer response to taxane 
treatment, which may be linked to their increased levels of CYP3A4, an oxidising enzyme which transforms 
docetaxel into inactive hydroxylated derivatives65. Importantly, CYP3A4, whose expression levels correlate with 
WT1 both in vivo and in vitro, is activated by VDR66, a known WT1 target67.
As a whole, this study has shown that WT1 can disrupt the epithelial-mesenchymal balance of breast cancer 
lines in opposite ways, depending on the baseline characteristics of the cells.
In breast tumours however, the WT1-expressing tumours are mainly associated with a mesenchymal pheno-
type and high levels of CYP3A4: therefore, their cells not only respond poorly to taxane, but they are also more 
likely to invade the blood vessels and metastasise.
In conclusion, we demonstrate that cancer-related EMT and poor chemotherapy response are likely the main 
factors that explain why WT1 expression in breast cancer is usually associated with poor prognosis.
Methods
Cell culture. The human breast cancer cell lines MDA-MB-157, MDA-MB-231, MDA-MB-453, MDA-MB-
435S, HBL100, MCF7, BT20, SKBR3, T47D, HS578T and ZR75 were maintained in DMEM medium (Sigma); 
BT474 and BT549 cell lines in RPMI medium (Sigma). Both media were supplemented with 10% fetal bovine 
serum (FBS), 2 mM L-glutamine, 100 units/mL penicillin and 100 mg/ml streptomycin. The human embryonic 
kidney cell line SODK3 used for the lentiviral packaging was maintained in DMEM-HIGH (Sigma) supple-
mented with 10% FBS, 2 mM L-glutamine, 100 units/mL penicillin, 100 mg/ml streptomycin, 1 μ g/ml puromycin, 
600 μ g/ml neomycin and 1 μ g/ml doxycycline. All lines were kept at standard cell culture conditions (37 °C, 5% 
CO2 in humidified incubator). Tet System Approved FBS (Clontech) was used in the culture media of TRIPZ-
transduced cells, to ensure that the inducible regulation of the system was not altered by the presence tetracy-
cline-derived contaminants.
Clinical samples. The use of tissue from invasive breast cancer patients treated at the Edinburgh Breast Unit 
at the Western General Hospital was approved by the Lothian Research Ethics Committee (08/S1101/41). This 
study was carried out in accordance with the approved guidelines and written informed consent was obtained 
from all subjects. Multiple core biopsies were harvested from consenting patients at the time of curative surgical 
resection for invasive breast cancer. Macroscopically distinct fat was trimmed and discarded. Tumour samples 
were then stored at − 80 °C until use.
shRNA-based stable WT1 knockdown and transient WT1 overexpression. The lentiviral 
GIPZ-shRNAmir-GFP and TRIPZ-shRNAmir-RFP vectors (Thermo Scientific Open Biosystems) were used 
as backbones for the cloning of shRNAs targeting the human WT1 transcript and a lacZ control (Figure S7 in 
Additional file 1, Table S4 in Additional file 2).
The final constructs were transduced using a trans-lentiviral packaging system developed in the human 
embryonic kidney cell line SODK368, which expresses GFP and all trans-lentivirus packaging proteins from a 
Tet-Off system. To activate the packaging system, the cells were grown for 3 days without doxycycline and FACS 
sorted for GFP expression; the brightest 15% was plated on a 0.001% poly-L-Lysine coated plate and grown over-
night without doxycycline. The following day, the SODK3 cells were transfected with the lentiviral vectors using 
FuGene6 (Roche) as per manufacturer’s instructions; the medium, containing 5 mM sodium butyrate (Sigma) 
but no doxycycline, was changed at 12 and 36 hours post-transfection. 72 hours after the last medium change, the 
virus-containing supernatants were harvested and centrifuged for 20 minutes at 4 °C to pellet cell debris. Standard 
procedures were used to transduce MDA-MB-157, MDA-MB-231 and HBL100 cells, which were maintained on 
selective media (1 μ g/ml puromycin) from day 2 post-transduction.
Full-length WT1 cDNA was amplified and cloned into the pCI mammalian expression vector using In-Fusion 
(Clontech). Cells were transfected with pCI-WT1-OE or the empty vector (Figure S7 in Additional file 1) and 
harvested after 30 h.
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Cytotoxicity assay. Cells were plated onto 96-well plates (5 × 103 cells/well) and after 24 hours the culture 
medium was replaced by fresh medium containing 40 nM docetaxel or DMSO. The cells were incubated for 
another 24, 48 and 72 h, then washed with PBS, fixed in cold methanol and stained with 0.5% crystal violet for 
30 minutes. After adding 100 μ l Sorenson buffer/well, absorbance was measured as a read-out of viable cells.
Animal experiments. Lung colonization experiments were performed in compliance with the UK Animals 
(Scientific Procedures) Act 1986, under Project Licence PPL 60/3788 approved by the UK Home Office. 1 × 106 
cells suspended in 100 μ l sterile PBS were directly injected into the lateral tail vein of 4-week-old female athymic 
nude mice. Lung metastases were identified by histological staining of paraffin sections with hematoxylin and 
eosin. The slides were scanned with a Hamamatsu nanozoomer slide scanner (Hamamatsu, UK), and then exam-
ined by two boarded pathologists -blinded to the experimental groups- for the presence of metastases using 
Hamamatsu NDP2 view software (Hamamatsu, UK). One representative section was chosen for each pulmonary 
lobe available for examination and measured. The measurements included total number of metastatic deposits, 
and the relative area of metastasis, expressed as total metastatic area/total lobe area for each sample.
Colony forming assay. Sphere formation was induced by culturing the cancer cells in suspension in 
serum-free medium (DMEM-F12 + GlutaMAX-I, Life Technologies) supplemented with B27 (1:50, Life 
Technologies), 20 ng/mL EGF (R&D), 0.4% bovine serum albumin (Sigma), 4 μ g/mL insulin (Sigma). To 
quantify colony formation, cells were plated at a density of 1,000 cells per well in 96-well plates coated with 
poly(2-hydroxyethyl metacrylate) to prevent cell attachment to the surface (Sigma); cells were diluted in sup-
plemented serum-free media containing 1% methylcellulose (Sigma) and the number of colonies > 75 μ m in 
diameter was counted after 11 days38.
Immunofluorescence microscopy. Cells were fixed for 15 minutes in 4% paraformaldehyde, rinsed with 
PBS and permeabilised for 10 minutes in 0.1% Triton X-100. Nonspecific immunoglobulin binding was blocked 
with a 30 minute incubation in 3% bovine serum albumin + 0.1% Triton X-100. Primary antibodies (E-cadherin 
Cell Signalling 24E10, Vimentin Cell Signalling 5741P, Wt1 Abcam 89901, Cytokeratin18 Santa Cruz 31700) 
were diluted 1:100 in 1% bovine serum albumin + 0.1% Triton X-100. After overnight incubation at 4 °C, cells 
were rinsed with PBS, then incubated for 1 h at room temperature with secondary antibodies (1:500 Alexa Fluor 
Invitrogen) or Phalloidin (Invitrogen A12379). Vectashield with DAPI (Vector Laboratories) was used to coun-
terstain the nuclei and mount the slides.
Migration and invasion assays. Migration assays were performed on 24 well plates containing 8 μ m PET 
culture inserts (Fisher Scientific). For each experiment, 5 × 104 cells resuspended in serum-free media were 
applied to the upper chamber while the lower chamber was filled with 300 μ l medium with 10% FBS. Cells were 
then incubated under normal conditions for 3.5 hours.
The invasion assay was similar to the migration assay, except that the inserts were evenly coated with 1 mg/
ml Matrigel; 2.5 × 104 cells were added to the upper chamber and incubated for 24 h. For both assays, cells were 
fixed with methanol for 10 min and stained with 0.5% crystal violet for 30 min. After removing the cells on the 
upper side of the filters with cotton-tipped swabs, the cells on the underside of the filters were counted under a 
X20 objective lens in five randomly chosen fields.
Cancer stem cell markers, apoptosis and cell cycle analysis. For the analysis of cancer stem cell 
markers, 1 × 106 cells were resuspended in 100 μ l PBS/5% FBS and incubated in the antibody dilution shown in 
Table S5 in Additional File 2. The GIPZ-transduced cells were incubated with CD44-APC and CD24-PE anti-
bodies, the TRIPZ-transduced cells with CD44-APC and CD24-FITC. After a 15 minute incubation on ice, the 
cells were washed twice in PBS, resuspended in 100 μ l PBS/5% FBS and analysed. The Annexin V Apoptosis 
Detection Kit APC (eBioscience) was used according to the manufacturer’s instructions: cells were washed once 
and resuspended at a concentration of 1 × 106 cells/ml in the binding buffer provided with the kit; 5 μ l of the 
APC-conjugated antibody were added to 100 μ l of cell suspension and incubated for 15 minutes at room temper-
ature. After one wash, cells were resupended in 200 μ l of binding buffer and 1 μ g/ml DAPI (Sigma) was added 
immediately before the analysis. For cell cycle analysis, cells were trypsinised and resuspended in 1.2 ml PBS; 3 ml 
ice cold 95% ethanol were then added dropwise while vortexing, to obtain a final 70% ethanol solution where the 
cells were incubated for 30 minutes.
All experiments were performed on a FACSAriaII Flow Cytometer (Becton Dickinson), data were analysed 
using FlowJo software.
RNA extraction, quantitative real-time PCR and RNA sequencing. Total RNA was extracted using 
RNeasy Mini Kit (Qiagen) with on-column DNAse digestion as per manufacturer’s instructions; cDNA was syn-
thesized from 2 μ g total RNA using AMV reverse transcriptase (Roche) and oligo d(T) priming. All the quan-
titative Real Time PCR experiments were performed in triplicate on the Roche Lightcycler 480 system using 
Universal Probe Library probes and primers designed with the Universal Probe Library Assay Design Centre 
(Table S6 in Additional file 1). Relative quantification of gene expression was performed by calculating Δ Ct where 
Δ Ct = CtX – CtACTB. The fold change in gene expression between two samples was then determined by calcu-
lating 2− Δ Δ Ct. For RNA sequencing, total RNA was isolated as previously described and sent to GATC Biotech 
(Germany) for library preparation and sequencing on the Illumina HiSeq 2000 platform. The raw data were 
analysed using Galaxy (https://usegalaxy.org/) and have been deposited in NCBI’s Gene Expression Omnibus69, 
where they are accessible through GEO Series accession number GSE93636.
An RNA sample of human adult mammary gland was purchased from AMSBIO and retrotranscribed; the 
specimen consisted of a pool from 5 healthy donors of different age (36, 57, 76, 78 and 83 years old).
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Gene expression analysis. Raw data (.cel) files from seventeen Affymetrix U133A/plus2 primary breast 
tumour gene expression datasets were downloaded from NCBI GEO (GSE12276, GSE21653, GSE3744, GSE5460, 
GSE2109, GSE1561, GSE17907, GSE2990, GSE7390, GSE11121, GSE16716, GSE2034, GSE1456, GSE6532, 
GSE3494) or the caBIG (geral-00143) repositories, normalised, batch-corrected and analysed as previously 
described41. The molecular subtypes were assigned based upon the highest correlation to the Prat et al.70 cen-
troids applied to each dataset separately. The Affymetrix U133A primary breast tumour gene expression data-
set GSE2506554 was used to compare the response to taxane-anthracycline chemotherapy in WT1-positive and 
WT1-negative tumours.
Immunoblot analysis. Immunoblotting was performed according to standard procedures using antibod-
ies against WT1 (Novus Biologicals NBP1-40787, diluted 1/2000) and HSP90 (BD Bioscience 610419, diluted 
1/5000).
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